Discovery and early clinical development of 2-{6-[2-(3,5-dichloro-4- pyridyl)acetyl]-2,3-dimethoxyphenoxy}- N -propylacetamide (LEO 29102), a soft-drug inhibitor of phosphodiesterase 4 for topical treatment of atopic dermatitis
Development of orally available phosphodiesterase 4 (PDE4) inhibitors as anti-inflammatory drugs has been going on for decades. However, only roflumilast has received FDA approval. One key challenge has been the low therapeutic window observed in the clin
Felding, Jakob,S?rensen, Morten D.,Poulsen, Tina D.,Larsen, Jens,Andersson, Christina,Refer, Pia,Engell, Karen,Ladefoged, Lotte G.,Thormann, Thorsten,Vinggaard, Anne Marie,Hegardt, Pontus,S?hoel, Anders,Nielsen, Simon Feldb?k
p. 5893 - 5903
(2014/08/18)
METHODS FOR THE PREPARATION OF SUBSTITUTED ACETOPHENONES
The present application discloses novel methods for the preparation of pyrid-4-yl substituted acetophenones, in particular 2-{6-[2-(3,5-dichloro-pyridin-4-yl)-acetyl]-2,3-dimethoxy-phenoxy}-N-propyl-acetamide. The application also discloses novel stable c
-
(2014/07/08)
SUBSTITUTED ACETOPHENONES USEFUL AS PDE4 INHIBITORS
The present invention relates to a compound according to formula: (I); wherein X1, X2, X3, X4 and X5 independently of each other represent -CH- or N; or X3, X4 and X5
-
Page/Page column 71
(2008/12/06)
More Articles about upstream products of 1035572-38-3